Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma.
about
The role of small adaptor proteins in the control of oncogenic signalingr driven by tyrosine kinases in human cancerMitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant TransformationStructure and mechanism of activity-based inhibition of the EGF receptor by Mig6Identification of ubiquinol cytochrome c reductase hinge (UQCRH) as a potential diagnostic biomarker for lung adenocarcinomaEGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models.In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma.Type I γ Phosphatidylinositol Phosphate 5-Kinase i5 Controls the Ubiquitination and Degradation of the Tumor Suppressor Mitogen-inducible Gene 6Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.The induction of MIG6 under hypoxic conditions is critical for dormancy in primary cultured lung cancer cells with activating EGFR mutations.EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancer.Mig-6 deficiency cooperates with oncogenic Kras to promote mouse lung tumorigenesis.Rational Optimization of Tumor Suppressor-Derived Peptide Inhibitor Selectivity between Oncogene Tyrosine Kinases ErbB1 and ErbB2.Conformationally constrained peptides target the allosteric kinase dimer interface and inhibit EGFR activation.Conversion of MIG6 peptide from the nonbinder to binder of lung cancer-related EGFR by phosphorylation and cyclization.Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response.
P2860
Q26770682-C15B7D14-0B84-4FE2-83A0-17F6B338061CQ28548302-88E37EFB-40B6-4F79-8824-3FB125E4063BQ36683851-AB3ECECB-3B71-4427-B933-F0C6B7F869F6Q37058136-F858F139-4B76-47B0-B840-2B28723E63F9Q37682778-6F524DDE-1C4D-424D-8F60-6BC5F128EFF1Q38738104-CACE3AA6-58F4-44A3-9154-4FF3A3EF3889Q38750358-A314A7A8-C40E-4A70-ADF2-0122FE5568ACQ38881066-6D031856-4A4A-4CA6-951B-FC73426F5B1DQ39148511-D5DE4C6A-2F48-4EE6-9B42-32A3BFDED242Q47111538-5D83A069-EBF2-4DE8-9C42-D17FC463AC07Q47345427-23FA6FC8-858A-4E16-BE58-F99874DCDA8BQ47409545-79CF9CB2-E286-4E69-B62C-6A7518D2C213Q48660795-43730B3C-C581-4118-B287-893039B78BADQ50792383-E98A30DE-5459-49DD-A813-FCB2BF2505B6Q51090377-521D5096-C50B-4125-9418-09E6A2268B29
P2860
Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Loss of MIG6 Accelerates Initi ...... or-Driven Lung Adenocarcinoma.
@ast
Loss of MIG6 Accelerates Initi ...... or-Driven Lung Adenocarcinoma.
@en
type
label
Loss of MIG6 Accelerates Initi ...... or-Driven Lung Adenocarcinoma.
@ast
Loss of MIG6 Accelerates Initi ...... or-Driven Lung Adenocarcinoma.
@en
prefLabel
Loss of MIG6 Accelerates Initi ...... or-Driven Lung Adenocarcinoma.
@ast
Loss of MIG6 Accelerates Initi ...... or-Driven Lung Adenocarcinoma.
@en
P2093
P2860
P1433
P1476
Loss of MIG6 Accelerates Initi ...... or-Driven Lung Adenocarcinoma.
@en
P2093
Abhilash Venugopalan
Andreas Giannakou
Constance M Cultraro
Daniel Ritt
Deborah K Morrison
Heinz Hoschuetzky
Ilona Linnoila
Joshua D Webster
R Mark Simpson
Romi Biswas
P2860
P304
P356
10.1158/2159-8290.CD-14-0750
P577
2015-03-03T00:00:00Z